Want to see GB:IMM full AI Analyst Report?
IMM Stock Chart & Stats
4.50 p
-0.48 p(-10.67%)
At close: 4:00 PM EDT
4.50 p
-0.48 p(-10.67%)
Day’s Range― - ―
52-Week Range1.39 p - 19.40 p
Previous CloseN/A
Volume1.18M
Average Volume (3M)15.00M
Market Cap
£23.24M
Enterprise Value18.98M
Total Cash (Recent Filing)£1.35M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding623,911,400
10 Day Avg. Volume4,827,745
30 Day Avg. Volume14,996,625
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)44.28
Price to Sales (P/S)0.00
P/FCF Ratio-12.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageReported debt is essentially zero, which materially reduces near-term solvency risk and interest burden. For a cash-burning clinical-stage biotech, minimal debt preserves strategic optionality for R&D financing and partnership pacing without risking covenant pressure or forced asset sales.
Narrowing LossesNet loss narrowed (2025 net -1.8M vs larger prior-year losses), indicating structured cost reductions or efficiencies. Sustained reduced burn improves runway and attractiveness to partners or investors, enabling more runway for clinical milestones that determine long-term value.
Focused Clinical-stage StrategyA clear focus on autoimmune and inflammatory therapeutics concentrates technical expertise and development resources. For clinical-stage developers, a defined therapeutic niche supports targeted trial design, potential partner interest, and a clearer regulatory path versus unfocused research agendas.
Bears Say
Zero RevenueThe company reports zero revenue across recent years while operating losses persist, meaning no internal cash generation from products. Long-term viability depends on external financing or successful licensing; absent revenue, commercialization risk remains high and dilutive financings are likely.
Consistent Cash BurnOngoing negative operating and free cash flow indicate the company consumes cash to fund operations and trials. Persistent burn forces reliance on capital markets or partners, constraining long-term planning and exposing the firm to funding timing risk and potential dilution ahead of value-creating milestones.
Fragile Capital StructureVolatile equity (including a period of negative shareholders' funds) signals a thin capital base and previous solvency pressure. That fragility limits ability to absorb setbacks, increases financing costs or dilution risk, and weakens bargaining power in licensing or partnership negotiations.
ImmuPharma News
IMM FAQ
What was ImmuPharma PLC’s price range in the past 12 months?
ImmuPharma PLC lowest share price was 1.39 p and its highest was 19.40 p in the past 12 months.
What is ImmuPharma PLC’s market cap?
ImmuPharma PLC’s market cap is £23.24M.
When is ImmuPharma PLC’s upcoming earnings report date?
ImmuPharma PLC’s upcoming earnings report date is Sep 24, 2026 which is in 42 days.
How were ImmuPharma PLC’s earnings last quarter?
ImmuPharma PLC released its earnings results on May 27, 2026. The company reported 0 p earnings per share for the quarter, the consensus estimate of N/A by 0 p.
Is ImmuPharma PLC overvalued?
According to Wall Street analysts ImmuPharma PLC’s price is currently Overvalued.
Does ImmuPharma PLC pay dividends?
ImmuPharma PLC pays a Notavailable dividend of 1 p which represents an annual dividend yield of N/A. See more information on ImmuPharma PLC dividends here
What is ImmuPharma PLC’s EPS estimate?
ImmuPharma PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImmuPharma PLC have?
ImmuPharma PLC has 623,911,400 shares outstanding.
What happened to ImmuPharma PLC’s price movement after its last earnings report?
ImmuPharma PLC reported an EPS of 0 p in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -4.333%.
Which hedge fund is a major shareholder of ImmuPharma PLC?
Currently, no hedge funds are holding shares in GB:IMM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ImmuPharma PLC
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company’s lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140, which is in Phase II clinical trial for the treatment of chronic inflammatory demyelinating polyneuropathy, a rare acquired autoimmune disorder of peripheral nerve; and P140 that covers other indications acute and chronic asthma, gout, irritable bowel disease, and periodontitis. Its pre-clinical products include BioAMB, a peptide-based drug of Amphotericin-B formulations for the treatment of serious and life-threatening fungal infections, such as aspergillosis; and BioCin, a vancomycin based treatment for anti-infection. It has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of 1P40 platform; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
Technical Analysis
Sareum Holdings
―
Scancell Holdings
―
HemoGenyx Pharmaceuticals Plc
―
SkinBioTherapeutics
―
Poolbeg Pharma Ltd.
―